Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors

Oncologist

Volumn 13, Issue 4, 2008, Pages 382-389

  Khanna, Geetika ^a   Bushnell, David ^a   O'Dorisio, M Sue ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Embryonal tumors; Neuroendocrine tumors; Pediatric; Pentetreotide; Scintigraphy; Somatostatin

Indexed keywords

IODINE 123; PENTETREOTIDE; SOMATOSTATIN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE DURATION; HISTOPATHOLOGY; HUMAN; MEDULLOBLASTOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TUMOR CELL;

AGE FACTORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; NEOPLASM STAGING; NEOPLASMS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROBLASTOMA; NEUROENDOCRINE TUMORS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 43549100216     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0175     Document Type: Review

References (65)

1. Epelbaum J. Somatostatin in the central nervous system: Physiology and pathological modifications. Prog Neurobiol 1986;27:63-100.
2. Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: Current concepts on diagnostic and therapeutic use. J Nucl Med 2005;46(suppl 1):55S-61S
3. Matthay KK. Neuroblastoma: A clinical challenge and biologic puzzle. CA Cancer J Clin 1995;45:179-192.
4. Reddy AT, Janss AJ, Phillips PC et al. Outcome for children with supra-tentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000;88:2189-2193.
5. Bakker WH, Krenning EP, Reubi JC et al. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593-1601.
6. Bakker WH, Krenning EP, Breeman WA et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990;31:1501-1509.
7. Bakker WH, Albert R, Bruns C et al. [111In-DTPA-D-Phe1]- octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-1591.
8. Balon HR, Goldsmith SJ, Siegel BA et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42:1134-1138.
9. Spix C, Pastore G, Sankila R et al. Neuroblastoma incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2081-2091.
10. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216.
11. O'Dorisio MS, Chen F, O'Dorisio TM et al. Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth Differ 1994;5:1-8.
12. Albers AR, O'Dorisio MS, Balster DA et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept 2000;88:61-73.
13. Lumbroso J, Guermazi F, Hartmann O et al. [Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: Analysis of 115 cases.] Bull Cancer 1988;75:97-106. French.
14. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours. Eur J Nucl Med 1994;21:561-581.
15. Schilling FH, Bihl H, Jacobsson H et al. Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol 2000;35:688-691.
16. Orlando C, Raggi CC, Bagnoni L et al. Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium-111- pentetreotide. Med Pediatr Oncol 2001;36:224-226.
17. Raggi CC, Maggi M, Renzi D et al. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab 2000;85:3866-3873.
18. Briganti V, Sestini R, Orlando C et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3:2385-2391.
19. Statistical Report: Primary Brain Tumors in the United States, 1998-2002, 2005-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States, 2005:1-55.
20. Steliarova-Foucher E, Stiller C, Lacour B et al. International Classification of Childhood Cancer, third edition. Cancer 2005;103:1457-1467.
21. Scheidhauer K, Hildebrandt G, Luyken C et al. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: First experiences. Horm Metab Res Suppl 1993;27:59-62.
22. Schmidt M, Scheidhauer K, Luyken C et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998;25:675-686.
23. Lee JD, Kim DI, Lee JT et al. Indium-111-pentetreotide imaging in intraaxial brain tumors: Comparison with thallium-201 SPECT and MRI. J Nucl Med 1995;36:537-541.
24. Reubi JC, Lang W, Maurer R et al. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987;47:5758-5764.
25. Müller HL, Frühwald MC, Scheubeck M et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurooncol 1998;38:27-40.
26. Frühwald MC, O'Dorisio MS, Pietsch T et al. High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: Implications for diagnosis and therapy. Pediatr Res 1999;45:697-708.
27. Frühwald MC, Rickert CH, O'Dorisio MS et al. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res 2004;10:2997-3006.
28. Khanna G, O'Dorisio MS, Menda Y et al. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatr Blood Cancer 2008;50:561-566.
29. Yüksel M, Lutterbey G, Biersack HJ et al. 111In-pentetreotide scintigraphy in medulloblastoma:Acomparison with magnetic resonance imaging. Acta Oncol 2007;46:111-117.
30. 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir (Wien) 1994;127:60-64.
31. Mawrin C, Schulz S, Pauli SU et al. Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas. J. Neuropathol Exp Neurol 2004;63:13-19.
32. Haldemann AR, Rösler H, Barth A et al. Somatostatin receptor scintigraphy in central nervous system tumors: Role of blood-brain barrier permeability. J Nucl Med 1995;36:403-410.
33. Guyotat J, Champier J, Jouvet A et al. Differential expression of somatostatin receptors in ependymoma: Implications for diagnosis. Int J Cancer 2001;95:144-151.
34. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
35. Spunt SL, Pratt CB, Rao BN et al. Childhood carcinoid tumors: The St Jude Children's Research Hospital experience. J Pediatr Surg 2000;35:1282-1286.
36. Broaddus RR, Herzog CE, Hicks MJ. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med 2003;127:1200-1203.
37. Khanna G, O'Dorisio MS, Menda Y et al. Gastroenteropancreatic neuroendocrine tumors in children and young adults. Pediatr Radiol 2008;38:251-259.
38. Ezziddin S, Logvinski T, Yong-Hing C et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2006;47:223-233.
39. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol 2001;12(suppl 2):S47-S50.
40. Guillermet-Guibert J, Lahlou H, Pyronnet S et al. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: Molecular aspects. Best Pract Res Clin Gastroenterol 2005;19:535-551.
41. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
42. Pfannenberg AC, Eschmann SM, Horger M et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 2003;30:835-843.
43. Krausz Y, Keidar Z, Kogan I et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59:565-573.
44. 3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518.
45. Cholewinski W, Kowalczyk JR, Stefaniak B et al. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide. Eur J Nucl Med Mol Imaging 2004;31:820-824.
46. de Krijger RR. Endocrine tumor syndromes in infancy and childhood. Endocr Pathol 2004;15:223-226.
47. Reubi J, Macke H, Krenning E. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46(suppl 1):67S-75S.
48. 90Y -DOTATOC. J Nucl Med 2002;43:610-616.
49. Otte A, Herrmann R, Heppeler A et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439-1447.
50. 3]octreotate. J Clin Oncol 2004;22:2724-2729.
51. Safford SD, Coleman RE, Gockerman JP et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101:1987-1993.
52. 131I-meta- iodobenzylguanidine in the management of metastatic midget carcinoid tumors. World J Surg 2004;28:1157-1162.
53. Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(suppl 1):62S-66S.
54. 131I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003;15:193-198.
55. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-2762.
56. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 2003;44:1556-1560.
57. 3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147-156.
58. 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005;44:232-239.
59. Lashford LS, Lewis IJ, Fielding SL et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889-1896.
60. 131I-MIBG. J Nucl Med 2001;42:1713-1721.
61. Quigley AM, Buscombe JR, Gopinath G et al. In-vivo characterisation of the functional aspects of carcinoid tumors by imaging somatostatin receptors and amine uptake. J Nucl Med 2003;44(suppl 5):74P.
62. 111In- pentetreotide in carcinoid tumours. Eur J Cancer 1996;32A:1924-1932.
63. 3-octreotide radiopeptide brachytherapy. Cancer 2005;103:869-873.
64. 3-octreotate. J Nucl Med 2005;46(suppl 1):83S-91S.
65. Rolleman EJ, Valkema R, de Jong M et al. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imag 2003;30:9-15.